Список литературы

Основные статьи

World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015 [internet publication].Полный текст

Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. July 2019 [internet publication].Полный текст

World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].Полный текст

Статьи, указанные как источники

1. Centers for Disease Control and Prevention. HIV infection: detection, counseling, and referral. In: Workowski KA, Bolan GA (eds). Sexually transmitted treatment guidelines, 2015. MMWR. 2015 5 June;(64):21-5.Полный текст

2. World Health Organization. HIV/AIDS: online QA. November 2017 [internet publication].Полный текст

3. Worobey M. The origins and diversifications of HIV. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008.

4. Wilson D, Naidoo S, Bekker LG, et al. Handbook of HIV medicine. South Africa: Oxford University Press; 2002.

5. Robertson DL, Anderson JP, Bradac JL, et al. HIV-1 nomenclature proposal. Science. 2000 Apr 7;288(5463):55-6. Аннотация

6. Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2018 Nov 30. pii: S1473-3099(18)30647-9. Аннотация

7. Yamaguchi J, McArthur C, Vallari A, et al. Complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):319-22. Аннотация

8. Gottlieb GS, Raugi DN, Smith RA. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV. 2018 Jul;5(7):e390-9. Аннотация

9. Fidler S, Fox J. Primary HIV infection: a medical and public health emergency requiring rapid specialist management. Clin Med (Lond). 2016 Apr;16(2):180-3.Полный текст  Аннотация

10. Joint United Nations Programme on HIV/AIDS. UNAIDS data 2019. 2019 [internet publication].Полный текст

11. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019 Dec;6(12):e831-9.Полный текст  Аннотация

12. Li Z, Purcell DW, Sansom SL, et al. Vital signs: HIV transmission along the coninuum of care - United States, 2016. MMWR Morb Mortal Wkly Rep. 2019 Mar 22;68(11):267-72.Полный текст  Аннотация

13. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2018 - 2017 data. November 2018 [internet publication].Полный текст

14. Public Health England. Trends in new HIV diagnoses and in people receiving HIV-related care in the United Kingdom: data to the end of December 2018. September 2019 [internet publicaton].Полный текст

15. Public Health England. Prevalence of HIV infection in the UK in 2018. November 2019 [internet publication].Полный текст

16. Brown AE, Mohammed H, Ogaz D, et al. Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)? Euro Surveill. 2017 Jun 22;22(25):30553.Полный текст  Аннотация

17. Centers for Disease Control and Prevention. HIV surveillance report: diagnoses of HIV infection in the United States and dependent areas, 2017; volume 29. November 2018 [internet publication].Полный текст

18. Centers for Disease Control and Prevention. CDC data confirm: progress in HIV prevention has stalled. February 2019 [internet publication].Полный текст

19. Pope M, Hause AT. Transmission, acute HIV-1 infection and the quest to prevent infection. Nat Med. 2003 Jul;9(7):847-52. Аннотация

20. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008 Sep 1;47(5):712-22.Полный текст  Аннотация

21. Morris L, Cilliers T. Viral structure, replication, tropism, pathogenesis and natural history. In: Abdool Karim SS, Abdool Karim Q, eds. HIV/AIDS in South Africa. Cambridge University Press; 2005:79-89.

22. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Def Syndr Hum Retrovirol. 1995 Oct 1;10(2):175-6. Аннотация

23. Varghese B, Maher JE, Peterman TA, et al. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis. 2002 Jan;29(1):38-43. Аннотация

24. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992 Mar 28;304(6830):809-13.Полный текст  Аннотация

25. Bell DM. Occupational risk of human immunodeficiency virus infection in health care workers: an overview. Am J Med. 1997 May 19;102(5B):9-15. Аннотация

26. Cooper ER, Charurat M, Mofenson L, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94. Аннотация

27. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016 Nov 13;30(17):2665-83.Полный текст  Аннотация

28. Tepper NK, Krashin JW, Curtis KM, et al. Update to CDC's US medical eligibility criteria for contraceptive use, 2016: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection. MMWR Morb Mortal Wkly Rep. 2017 Sep 22;66(37):990-4.Полный текст  Аннотация

29. World Health Organization. Contraceptive eligibility for women at high risk of HIV: guidance statement - recommendations on contraceptive methods used by women at high risk of HIV. 2019 [internet publication].Полный текст

30. Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017 Dec;17(12):1303-16.Полный текст  Аннотация

31. Looker KJ, Welton NJ, Sabin KM, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis. 2020 Feb;20(2):240-9.Полный текст  Аннотация

32. Riddell J 4th, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018 Mar 27;319(12):1261-8. Аннотация

33. Delaugerre C, Rodriguez C, Capitant C, et al. Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. AIDS. 2018;32(16):2353-61. Аннотация

34. Desai M, Field N, Grant R, et al. Recent advances in pre-exposure prophylaxis for HIV. BMJ. 2017 Dec 11;359:j5011.Полный текст  Аннотация

35. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015 [internet publication].Полный текст

36. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019 Jun 11;321(22):2203-13.Полный текст  Аннотация

37. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2017 update. March 2018 [internet publication].Полный текст

38. Cohen SE, Sachdev D, Lee SA, et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018 Nov 29 [Epub ahead of print]. Аннотация

39. Tumarkin E, Siedner MJ, Bogoch II. The BMJ 10-minute consultation: HIV pre-exposure prophylaxis (PrEP). BMJ. 2019 Jan 17;364:k4681.

40. Coelho LE, Torres TS, Veloso VG, et al. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019 Nov;6(11):e788-9. Аннотация

41. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24;320(4):379-96.Полный текст  Аннотация

42. Antoni G, Tremblay C, Delaugerre C, et al. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV. 2020 Feb;7(2):e113-20. Аннотация

43. Grulich AE, Guy R, Amin J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018 Nov;5(11):e629-37. Аннотация

44. Holt M, Lea T, Mao L, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17. Lancet HIV. 2018 Aug;5(8):e448-56. Аннотация

45. Finlayson T, Cha S, Xia M, et al; National HIV Behavioral Surveillance Study Group. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men - 20 urban areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603.Полный текст  Аннотация

46. Anglemyer A, Rutherford GW, Horvath T, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009153.Полный текст  Аннотация

47. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.Полный текст  Аннотация

48. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016 Jul 12;316(2):171-81.Полный текст  Аннотация

49. Bavinton BR, Pinto AN, Phanuphak N, et al; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018 Aug;5(8):e438-47. Аннотация

50. PARTNER Study Group. HIV transmission risk through condomless sex in gay couples with suppressive ART: the PARTNER2 Study extended results in gay men. 2018 [internet publication].Полный текст

51. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019 Jun 15;393(10189):2428-38.Полный текст  Аннотация

52. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. July 2019 [internet publication].Полный текст

53. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007 Feb 24;369(9562):657-66. Аннотация

54. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007 Feb 24;369(9562):643-56. Аннотация

55. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005 Nov;2(11):e298.Полный текст  Аннотация

56. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systemic review and meta-analysis. AIDS. 2000 Oct 20;14(15):2361-70. Аннотация

57. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009 Mar 26;360(13):1298-309.Полный текст  Аннотация

58. Mills E, Cooper C, Anema A, et al. Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med. 2008 Jul;9(6):332-5. Аннотация

59. Delany-Moretlwe S, Gray G, Kagee A, et al. AIDS prevention in South Africa. South Afr J HIV Med. 2006;23:13-7.

60. Rubens M, Ramamoorthy V, Saxena A, et al. HIV vaccine: recent advances, current roadblocks, and future directions. J Immunol Res. 2015;2015:560347.Полный текст  Аннотация

61. Leal L, Lucero C, Gatell JM, et al. New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017 Jun;16(6):587-600. Аннотация

62. Marshall BDL, Goedel WC, King MRF, et al. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. Lancet HIV. 2018 Sep;5(9):e498-505.Полный текст  Аннотация

63. Centers for Disease Control and Prevention. Laboratory testing for the diagnosis of HIV infection: updated recommendations. June 2014 [internet publication].Полный текст

64. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection: United States, 2014. MMWR Recomm Rep. 2014;63(RR-03):1-10.Полный текст  Аннотация

65. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].Полный текст

66. UNAIDS, World Health Organization. UNAIDS/WHO policy statement on HIV testing. June 2004 [internet publication].Полный текст

67. World Health Organization. HIV drug resistance report 2019. July 2019 [internet publication].Полный текст

68. Shepher J, Quinn T. Laboratory testing for HIV infection. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008:101-7.

69. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15;49(10):1582-90.Полный текст  Аннотация

70. Aves T, Tambe J, Siemieniuk RA, et al. Antiretroviral resistance testing in HIV-positive people. Cochrane Database Syst Rev. 2018 Nov 9;(11):CD006495.Полный текст  Аннотация

71. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: sexual assault and abuse and STDs. June 2015 [internet publication].Полный текст

72. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. July 2017 [internet publication].Полный текст

73. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17;quiz CE1-4.Полный текст  Аннотация

74. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):830-2.Полный текст  Аннотация

75. Pitasi MA, Oraka E, Clark H, et al. HIV testing among transgender women and men - 27 states and Guam, 2014-2015. MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):883-7.Полный текст  Аннотация

76. Pitasi MA, Delaney KP, Oraka E, et al. Interval since last HIV test for men and women with recent risk for HIV infection - United States, 2006-2016. MMWR Morb Mortal Wkly Rep. 2018 Jun 22;67(24):677-81.Полный текст  Аннотация

77. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019 Jun 18;321(23):2326-36.Полный текст  Аннотация

78. The Voluntary HIV Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania and Trinidad: a randomised trial. Lancet. 2000 Jul 8;356(9224):103-12. Аннотация

79. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. September 2019 [internet publication].Полный текст

80. Grobler L, Siegfried N, Visser ME, et al. Nutritional interventions for reducing morbidity and mortality in people with HIV. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004536.Полный текст  Аннотация

81. Olsen MF, Abdissa A, Kaestel P, et al. Effects of nutritional supplementation for HIV patients starting antiretroviral treatment: randomised controlled trial in Ethiopia. BMJ. 2014 May 15;348:g3187.Полный текст  Аннотация

82. Visser ME, Durao S, Sinclair D, et al. Micronutrient supplementation in adults with HIV infection. Cochrane Database Syst Rev. 2017 May 18;(5):CD003650.Полный текст  Аннотация

83. US Department of Health and Human Services. HIV and immunizations. January 2019 [internet publication].Полный текст

84. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27;373(9):795-807.Полный текст  Аннотация

85. Mateo-Urdiales A, Johnson S, Smith R, et al. Rapid initiation of antiretroviral therapy for people living with HIV. Cochrane Database Syst Rev. 2019 Jun 17;(6):CD012962.Полный текст  Аннотация

86. Feng Q, Zhou A, Zou H, et al. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019 Jul 8;366:l4179.Полный текст  Аннотация

87. National Institute for Health Research. NIHR Signal: Four-drug treatment for HIV offers no benefit over standard three-drug treatment. September 2019 [internet publication].Полный текст

88. Cahn P, Madero JS, Arribas J, et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection - 48-week results from the GEMINI studies. Paper presented at: 22nd International AIDS Conference (AIDS 2018). 2018. Amsterdam, Netherlands.Полный текст

89. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. December 2018 [internet publication].Полный текст

90. Wang H, Lu X, Yang X, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016 Oct;95(41):e5146.Полный текст  Аннотация

91. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: second edition June 2016. July 2017 [internet publication].Полный текст

92. Lennox JL, Landovitz RJ, Ribaudo HJ, et al; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461-71.Полный текст  Аннотация

93. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011 Oct 15;204(8):1217-26.Полный текст  Аннотация

94. Lindegren ML, Kennedy CE, Bain-Brickley D, et al. Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and family planning services. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD010119.Полный текст  Аннотация

95. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-analysis. HIV Med. 2012 Sep;13(8):453-68. Аннотация

96. Segarra-Newnham M. Osteoporosis and vitamin D deficiency in HIV-positive patients. J Pharm Technol. 2011;27:251-7.

97. Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018 Aug 16;379(7):645-54.Полный текст  Аннотация

98. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23;390(10101):1499-510. Аннотация

99. Li L, Tian JH, Yang K, et al. Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection. Cochrane Database Syst Rev. 2014 Jul 26;(7):CD008439.Полный текст  Аннотация

100. Lalezari JP, Latiff GH, Brinson C, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015 Oct;2(10):e427-37. Аннотация

101. Murgatroyd C, Pirrie L, Tran F, et al. Structure-activity relationships of the human immunodeficiency virus type 1 maturation inhibitor PF-46396. J Virol. 2016 Aug 26;90(18):8181-97.Полный текст  Аннотация

102. ClinicalTrials.gov. Attachment inhibitor comparison in heavily treatment experienced patients. August 2019 [internet publication].Полный текст

103. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003 May 12;163(9):1009-21.Полный текст  Аннотация

104. O'Connor J, Smith C, Lampe FC, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017 Jul;4(7):e295-302.Полный текст  Аннотация

105. Nance RM, Delaney JAC, Simoni JM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376-84.Полный текст  Аннотация

106. Teeraananchai S, Kerr SJ, Amin J, et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017 Apr;18(4):256-66. Аннотация

107. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349-56.Полный текст  Аннотация

108. Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis. 2017 Aug 15;65(4):636-43.Полный текст

109. Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019 Apr;568(7751):244-8. Аннотация

110. NHS (UK). Behind the headlines: stem cell cancer treatment leaves man 'free' of HIV. March 2019 [internet publication].Полный текст

111. Mandalia S, Westrop SJ, Beck EJ, et al. Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988-2010. PLoS One. 2012;7(2):e29844.Полный текст  Аннотация

112. Lawn SD, Wilkinson RJ, Lipman MC, et al. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Resp Crit Care Med. 2008 Apr 1;177(7):680-5. Аннотация

113. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138(11):1100-12.Полный текст  Аннотация

114. Losina E, Hyle EP, Borre ED, et al. Projecting 10-yr, 20-yr and lifetime risks of cardiovascular disease in persons living with HIV in the US. Clin Infect Dis. 2017 Oct 15;65(8):1266-71. Аннотация

115. Beckman JA, Duncan MS, Alcorn CW, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation. 2018 Jul 17;138(3):255-65.Полный текст  Аннотация

116. Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018 Jun;5(6):e291-300. Аннотация

117. Osibogun O, Ogunmoroti O, Michos ED, et al. HIV/HCV coinfection and the risk of cardiovascular disease: a meta-analysis. J Viral Hepat. 2017 Nov;24(11):998-1004. Аннотация

118. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019 Jul 9;140(2):e98-124. Полный текст  Аннотация

119. Howard JFB, Rokx C, Smit C, et al. Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study. Lancet HIV. 2019 Mar;6(3):e173-81. Аннотация

120. Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015 Mar 15;60(6):941-9.Полный текст  Аннотация

121. Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015 Dec;22(6):446-51. Аннотация

122. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009 Jan 2;23(1):41-50.Полный текст  Аннотация

123. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013 Sep;57(5):756-64.Полный текст  Аннотация

124. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2551-9.Полный текст  Аннотация

125. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015 Oct 6;163(7):507-18.Полный текст  Аннотация

126. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014 May 15;28(8):1181-91. Аннотация

127. Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV. 2018 Nov;5(11):e647-55. Аннотация

128. Park LS, Tate JP, Sigel K, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study. Ann Intern Med. 2018 Jul 17;169(2):87-96. Аннотация

129. Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016;63:1160-7.Полный текст  Аннотация

130. Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep. 2014 Sep;11(3):317-24. Аннотация

131. Eshun-Wilson I, Siegfried N, Akena DH, et al. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018 Jan 22;(1):CD008525.Полный текст  Аннотация

132. Monroe AK, Glesby MJ, Brown TT, et al. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015 Feb 1;60(3):453-62.Полный текст  Аннотация

133. Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab Res Rev. 2017 Sep;33(6). Аннотация

134. Bhatia R, Murphy AB, Raper JL, et al. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems. AIDS. 2015 Jan 2;29(1):77-81.Полный текст  Аннотация

135. Crothers K, Morris A. HIV infection and lung function decline: challenges, clinical implications, and new questions. AIDS. 2013 May 15;27(8):1345-7. Аннотация

136. Ensink RJH, Kuper H. Is hearing impairment associated with HIV? A systematic review of data from low- and middle-income countries. Trop Med Int Health. 2017 Dec;22(12):1493-504. Аннотация

137. Kuhar DT, Henderson DK, Struble KA, et al; US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92.Полный текст  Аннотация

138. Centers for Disease Control and Prevention, US Department of Health and Human Services. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV - United States, 2016. April 2018 [internet publication].Полный текст

139. Brooks JT, Kawwass JF, Smith DK, et al. Effects of antiretroviral therapy to prevent HIV transmission to women in couples attempting conception when the man has HIV infection - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 18;66(32):859-60.Полный текст  Аннотация

140. Kawwass JF, Smith DK, Kissin DM, et al. Strategies for preventing HIV infection among HIV-uninfected women attempting conception with HIV-infected men - United States. MMWR Morb Mortal Wkly Rep. 2017 Jun 2;66(21):554-7.Полный текст  Аннотация

141. National Institute for Health and Care Excellence. HIV testing: increasing uptake among people who may have undiagnosed HIV. December 2016 [internet publication].Полный текст

142. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168-74.Полный текст  Аннотация

143. Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):230-9. Аннотация

Использование этого контента попадает под действие нашего заявления об отказе от ответственности